TRPM8 receptor antagonists
Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: Wherein R is selected from: H, Br, CN, NO 2 , SO 2 NH 2 , SO 2 NHR′ and SO 2 NR′ 2 , where R′ is selected from linear or branched C 1 -C 4 alkyl; X is selected from: F, Cl, C 1 -C 3 alkyl, NH 2 and OH Y is selected from: O, CH 2 , NH and SO 2 R1 and R2, independently one from the other, are selected from H, F and linear or branched C 1 -C 4 alkyl; R3 and R4, independently one from the other, are selected from H and linear or branched C 1 -C 4 alkyl; Z is selected from: NR6 and R6R7N + , where R6 and R7 independently one from the other, are selected from: H and linear or branched C 1 -C 4 alkyl R5 is a residue selected from: H and linear or branched C 1 -C 4 alkyl Het is a heteroaryl group selected from a substituted or not substituted pyrrolyl, a substituted or not substituted N-methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted or not substituted furyl and a substituted or not substituted pyridinyl. Said compounds are useful in the prevention and treatment of pathologies depending on TRPM8 activity such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.
1. A compound having formula (I):
and a pharmaceutically acceptable salt thereof,
wherein:
R is selected from:
H, Br, CN, NO 2 , SO 2 NH 2 , SO 2 NHR′ and SO 2 N(R′) 2 , where R′ is selected from linear or branched C 1 -C 4 alkyl;
X is selected from:
F, Cl, C 1 -C 3 alkyl, NH 2 and OH;
Y is selected from:
—O—, CH 2 , NH and SO 2 ;
R1 and R2, independently one from the other, are selected from
H, F and linear or branched C 1 -C 4 alkyl;
R3 and R4, independently one from the other, are selected from
H and linear or branched C 1 -C 4 alkyl;
Z is selected from:
NR6 and R6R7N + , where R6 and R7, independently one from the other, are selected from:
H and linear or branched C 1 -C 4 alkyl;
R5 is a residue selected from:
H and linear or branched C 1 -C 4 alkyl, and
Het is a heteroaryl group selected from pyrrolyl, N-methylpyrrolyl, thiophenyl, furyl and pyridinyl, unsubstituted or substituted with one or more substituents selected from F, Cl, CH 3 , NH 2 and OH.
2. The compound according to claim 1 , wherein, independently one from the other:
R is selected from H, Br and CN;
X is selected from F, Cl and C 1 -C 3 alkyl;
Y is selected from —O—, CH 2 , NH and SO 2 ;
R1 and R2, independently one from the other, are selected from H, F and CH 3 ;
R3 and R4, independently one from the other, are selected from H and CH 3 ;
Z is selected from NR6 and R6R7N + , where R6 and R7, independently one from the other, are selected from H and CH 3 ; and
R5 is selected from H and CH 3 .
3. The compound according to claim 1 , wherein, independently one from the other,
R is selected from H and CN;
X is selected from F and Cl;
Y is selected from CH 2 , O and SO 2 ;
Z is selected from NH and N + (CH 3 ) 2 ;
R5 is H; and
Het is substituted with at least one substituent selected from F, Cl and CH 3 .
4. The compound according to claim 1 , wherein Het is 5-substituted pyrrol-2-yl, 5-substituted N-methylpyrrol-2-yl, or 5-substituted thiophen-2-yl or 5-substituted fur-2-yl.
5. The compound according to claim 1 , selected from the group consisting of:
2-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanaminium chloride (1);
2-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]ethanaminium chloride (2);
N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]ethanaminium (3);
2-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]ethanaminium (4);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethy)ethanaminium (5);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethy)ethanaminium (6);
2-[(1-chloronaphthalen-2-yl)oxy]-N-[(1-methyl-1H-pyrrol-2-yl)methyl]ethanaminium (7);
1-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-2-methylpropan-2-amine (8);
1-[(1-chloronaphthalen-2-yl)oxy]-2-methyl-N-[(5-methylfuran-2-yl)methyl]propan-2-amine (9);
N-[(5-chlorofuran-2-yl)methyl]-1-[(1-chloronaphthalen-2-yl)oxy]-2-methylpropan-2-amine (10);
1-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]-2-methylpropan-2-amine (11);
1-[(1-chloronaphthalen-2-yl)oxy]-2-methyl-N-(thiophen-2-ylmethyl)propan-2-amin (12);
1-[(1-chloronaphthalen-2-yl)oxy]-2-methyl-N-(pyridin-2-ylmethyl)propan-2-amine (13);
1-[(1-chloronaphthalen-2-yl)oxy]-2-methyl-N- [(1-methyl-1H-pyrrol-2-yl)methyl]propan-2-amine (14);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)propan-1-amine (15);
2-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]propan-1-amine (16);
N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]propan-1-amine (17);
2-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]propan-1-amine (18);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)propan-1-amine (19);
1-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)propan-2-amine (20);
1-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]propan-2-amine (21);
N-[(5-chlorofuran-2-yl)methyl]-1-[(1-chloronaphthalen-2-yl)oxy]propan-2-amine (22);
1-[(1-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]propan-2-amine (23);
1-[(1-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)propan-2-amine (24);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-(furan-2-ylmethy)ethanamine (25);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-[(5-methylfuran-2-yl)methyl]ethanamine (26);
N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)sulfonyl]ethanamine (27);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-[(5-chlorothiophen-2-yl)methyl]ethanamine (28);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-(thiophen-2-ylmethy)ethanamine (29);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-(pyridin-2-ylmethy)ethanamine (30);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-[(1-methyl-1H-pyrrol-2-yl)methyl] ethanamine (31);
3-(1-chloronaphthalen-2-yl)-N-(furan-2-ylmethyl)propan-1-amine (32);
3-(1-chloronaphthalen-2-yl)-N-[(5-methylfuran-2-yl)methyl]propan-1-amine (33);
N-[(5-chlorofuran-2-yl)methyl]-3-(1-chloronaphthalen-2-yl)propan-1-amine (34);
3-(1-chloronaphthalen-2-yl)-N-[(5-chlorothiophen-2-yl)methyl]propan-1-amine (35);
3-(1-chloronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propan-1-amine (36);
3-(1-chloronaphthalen-2-yl)-N-(pyridin-2-ylmethyl)propan-1-amine (37);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-N-methylethanamine (38);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-N,N-dimethylethanaminium iodide (39);
N-{2-[(1-chloronaphthalen-2-yl)oxy]ethyl}-1-(5-methylfuran-2-yl)ethanamine (40);
N-(1-chloronaphthalen-2-yl)-N′-(furan-2-ylmethyl)ethane-1,2-diamine (41);
N-(1-chloronaphthalen-2-yl)-N′-[(5-methylfuran-2-yl)methyl]ethane-1,2-diamine (42);
N-[(5-chlorofuran-2-yl)methyl]-N′-(1-chloronaphthalen-2-yl)ethane-1,2-diamine (43);
N-(1-chloronaphthalen-2-yl)-N′-[(5-chlorothiophen-2-yl)methyl]ethane-1,2-diamine (44);
N-(1-chloronaphthalen-2-yl)-N′-(thiophen-2-ylmethy)ethane-1,2-diamine (45);
N-(1-chloronaphthalen-2-yl)-N′-(pyridin-2-ylmethy)ethane-1,2-diamine (46);
N-(1-chloronaphthalen-2-yl)-N′-[(1-methyl-1H-pyrrol-2-yl)methyl]ethane-1,2-diamine (47);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanamine (48);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]ethanamine (49);
N-[(5-chlorofuran-2-yl)methyl]-2-[(1-fluoronaphthalen-2-yl)oxy]ethanamine (50);
N-[(5-chlorothiophen-2-yl)methyl]-2-[(1-fluoronaphthalen-2-yl)oxy]ethanamine (51);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethy)ethanamine (52);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethy)ethanamine (53);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-[(1-methyl-1H-pyrrol-2-yl)methyl]ethanamine (54);
5-chloro-6-{2-[(pyridin-2-ylmethyl)amino]ethoxy}naphthalene-2-carbonitrile (55);
5-chloro-6-{2-[(furan-2-ylmethyl)amino]ethoxy}naphthalene-2-carbonitrile (56);
5-chloro-6-(2-{[(5-methylfuran-2-yl)methyl]amino}ethoxy)naphthalene-2-carbonitrile (57);
5-chloro-6-(2-{[(5-chlorofuran-2-yl)methyl]amino}ethoxy)naphthalene-2-carbonitrile (58);
5-chloro-6-(2-{[(5-chlorothiophen-2-yl)methyl]amino}ethoxy)naphthalene-2-carbonitrile (59);
5-chloro-6-{2-[(thiophen-2-ylmethyl)amino]ethoxy}naphthalene-2-carbonitrile (60);
2-[(1-ethylnaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanamine (61);
2,2-difluoro-2-[(1-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanamine (62); and
2-[(6-bromo-1-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanamine (63).
6. The compound according to claim 1 , selected from the group consisting of:
2-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanaminium chloride (1);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethy)ethanaminium (5);
2-[(1-chloronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethy)ethanaminium (6);
1-[(1-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-2-methylpropan-2-amine (8);
1-[(1-chloronaphthalen-2-yl)oxy]-2-methyl-N-(pyridin-2-ylmethyl)propan-2-amine (13);
1-[(1-chloronaphthalen-2-yl)oxy]-2-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]propan-2-amine (14);
2-[(1-chloronaphthalen-2-yl)sulfonyl]-N-(furan-2-ylmethy)ethanamine (25);
3-(1-chloronaphthalen-2-yl)-N-(furan-2-ylmethyl)propan-1-amine (32);
3-(1-chloronaphthalen-2-yl)-N-[(5-methylfuran-2-yl)methyl]propan-1-amine (33);
N-[(5-chlorofuran-2-yl)methyl]-3-(1-chloronaphthalen-2-yl)propan-1-amine (34);
3-(1-chloronaphthalen-2-yl)-N-[(5-chlorothiophen-2-yl)methyl]propan-1-amine (35);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethy)ethanamine (48);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethy)ethanamine (52);
2-[(1-fluoronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethy)ethanamine (53);
5-chloro-6-{2-[(pyridin-2-ylmethyl)amino]ethoxy}naphthalene-2-carbonitrile (55); and
5-chloro-6-{2-[(thiophen-2-ylmethyl)amino]ethoxy}naphthalene-2-carbonitrile (60).
7. A pharmaceutical composition comprising as the active ingredient at least one compound according claim 1 in combination with suitable excipients and/or diluents.
8. The pharmaceutical composition according to claim 7 , suitable to be administered by intravesical route, intravenous route, dermal route, oral route, and inhalatory route.
9. The pharmaceutical composition according to claim 7 , in the form of a controlled release formulation.
10. A method of preventing, treating, or preventing and treating disorders, diseases, or disorders and diseases associated with the activity of the TRPM8 (Transient Receptor Potential cation channel subfamily M member 8) selected from the group consisting of: inflammatory conditions, ischaemia, pain, urological disorders, stroke, psychiatric disorders and neurodegeneration, the method comprising administering a compound according to claim 1 .
11. The method according to claim 10 , wherein said disorders, diseases, or disorders and diseases are selected from chronic pain, neuropathic pain, postoperative pain, osteoarthritic pain, rheumatoid arthritic pain, cancer pain, neuralgia, fibromyalgia, neuropathies, algesia, nerve injury, migraine, headaches, itch, irritable bowel syndrome and respiratory diseases, bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, neurogenic detrusor overactivity, idiopathic detrusor overactivity, benign prostatic hyperplasia, lower urinary tract disorders and lower urinary tract symptoms, anxiety and depression.
12. The method of claim 11 , wherein said neuropathic pain is selected from cold allodynia and diabetic neuropathic pain.
13. A process for preparing the compound according to claim 1 , comprising:
reacting the aminic intermediate (IA):
wherein X , R1, R2, R3, R4 and Z have the same meanings as those of formula (I) and Y′=O, CH 2 , NH and S, with R5CO-Het, wherein Het and R5 have the same meanings as those of formula (I), and subsequently adding to the reaction mixture a mild reducing agent, thereby obtaining the compound (IB):
14. The process according to claim 13 , wherein the mild reducing agent is sodium borohydride.
15. The process according to claim 13 , wherein the compound (IB) coincides with formula (I) when Y′=O, CH 2 , or NH.
16. The process according to claim 13 , further comprising, when Y′=S, oxidizing the compound (IB) to yield the compound of formula (I) having Y=SO 2 .